Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-? Concentrations and Cognition Outcomes in?Alzheimer's Disease Patients: A?Multicenter, Randomized, Controlled Clinical Trial.

Boada M, Anaya F, Ortiz P, Olazar?n J, Shua-Haim JR, Obisesan TO, Hern?ndez I, Mu?oz J, Buendia M, Alegret M, Lafuente A, T?rraga L, N??ez L, Torres M, Grifols JR, Ferrer I, Lopez OL, P?ez A. Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-? Concentrations and Cognition Outcomes in?Alzheimer's Disease Patients: A?Multicenter, Randomized, Controlled Clinical Trial. J Alzheimers Dis. 2017; 56(1):129-143.

View in: PubMed

subject areas

authors with profiles

Thomas O. Obisesan

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support